Talis Biomedical Corporation (TLIS)
OTCMKTS · Delayed Price · Currency is USD
2.840
+1.240 (77.50%)
Inactive · Last trade price on Dec 18, 2025
Talis Biomedical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| 0.41 | 2.13 | 4.81 | 8.19 | 10.94 | 3.98 | |
Revenue Growth | -85.69% | -55.65% | -41.27% | -25.10% | 175.03% | 66.40% |
Cost of Revenue | 20.5 | 40.74 | 79.22 | 157.59 | 89.02 | 23.81 |
Gross Profit | -20.09 | -38.6 | -74.41 | -149.4 | -78.08 | -19.84 |
Selling, General & Admin | 26.26 | 25.45 | 37.14 | 42.42 | 13.1 | 6.86 |
Operating Expenses | 26.26 | 25.45 | 37.14 | 42.42 | 13.1 | 6.86 |
Operating Income | -46.35 | -64.05 | -111.55 | -191.82 | -91.18 | -26.7 |
Interest & Investment Income | - | - | - | - | - | 0.04 |
Other Non Operating Income (Expenses) | 4.1 | 4.81 | 2.13 | -0.22 | 0.05 | - |
EBT Excluding Unusual Items | -42.25 | -59.24 | -109.42 | -192.04 | -91.13 | -26.66 |
Asset Writedown | -8.77 | -2.77 | -3.59 | - | - | - |
Other Unusual Items | - | - | - | - | - | -0.82 |
Pretax Income | -51.03 | -62.01 | -113.01 | -192.04 | -91.13 | -27.47 |
Net Income | -51.03 | -62.01 | -113.01 | -192.04 | -91.13 | -27.47 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | -53.86 |
Net Income to Common | -51.03 | -62.01 | -113.01 | -192.04 | -91.13 | 26.38 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 0 | 0 |
Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 0 | 0 |
Shares Change | 0.57% | 0.95% | 19.21% | 968.49% | -1.41% | 309.45% |
EPS (Basic) | -28.02 | -34.12 | -62.77 | -127.15 | -644.69 | 515.03 |
EPS (Diluted) | -28.02 | -34.12 | -62.77 | -127.15 | -644.69 | -191.62 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Free Cash Flow | -40.24 | -53.73 | -101.75 | -174.25 | -95.23 | -24.9 |
Free Cash Flow Per Share | -22.09 | -29.56 | -56.51 | -115.37 | -673.66 | -173.70 |
Operating Margin | -11360.29% | -3001.36% | -2318.08% | -2341.22% | -833.64% | -671.34% |
Profit Margin | -12506.37% | -2905.67% | -2348.55% | -2343.90% | -833.15% | 663.36% |
Free Cash Flow Margin | -9861.52% | -2517.62% | -2114.53% | -2126.82% | -870.59% | -626.20% |
EBITDA | -45.58 | -63.28 | -102.72 | -190.24 | -90.42 | -25.97 |
D&A For EBITDA | 0.77 | 0.77 | 8.83 | 1.58 | 0.76 | 0.73 |
EBIT | -46.35 | -64.05 | -111.55 | -191.82 | -91.18 | -26.7 |
Revenue as Reported | 0.41 | 2.13 | 4.81 | 8.19 | - | - |